Objective: We aimed to investigate whether HIV latency in the CNS might have adverse molecular, pathologic, and clinical consequences.
Infection of the CNS by HIV is associated with neurologic conditions, from HIV-associated dementia (HAD) 1 to milder HIV-associated neurocognitive disorders (HAND). 2 Highly active antiretroviral therapy (HAART) helps prolong the life of infected patients, reducing the incidence of HAD. 3 Although cases with severe HIV-related cognitive impairment have decreased, the frequency of HIV encephalitis (HIVE), characterized by presence of infected macrophages in the CNS, microgliosis, astrogliosis, and myelin loss, has remained the same or slightly increased. [4] [5] [6] Complete eradication of HIV-1 is not feasible due to persistence of latent viral forms integrated into the host genome. 7 The brain represents a reservoir from which productive infections and chronic CNS injury might emerge, since resistance to HAART might allow residual viral replication, [8] [9] [10] highlighting the importance of host mechanisms mediating latency. In human microglial cells, the transcription factor BCL11B (also known as CTIP2) inhibits HIV transcription by recruiting a chromatin-modifying complex to the LTR region that results in HIV silencing. 11 Still, little is known about the mechanisms of HIV-1 latency in the human brain and their potential long-term effects. The persistence of latent virus in the brain might lead to cognitive impairment and neurodegeneration by gene expression alterations and proinflammatory responses.
We hypothesized that patients with latent HIV infection would display neurocognitive, neurodegenerative, and neuroinflammatory alterations similar to but milder than patients with HIVE. Increased levels of BCL11B and other components of the HIV silencing complex might deregulate neuroinflammatory cascades leading to the observed pathology in patients with latent HIV infection.
METHODS Study population. We included 32 HIV1 cases from the HIV Neurobehavioral Research Center (HNRC) and California NeuroAIDS Tissue Network at the University of California, San Diego (UCSD; table 1). Neurocognitive examination was available for 23 of the 32 cases studied. Subjects had neuromedical and neuropsychological examinations within a median of 12 months before death. Most individuals died as a result of acute bronchopneumonia or septicemia (table 1). Autopsy findings were consistent with AIDS and the associated systemic pathology found included disseminated cytomegalovirus and Mycobacterium avium infection, Pneumocystis carinii pneumonia, and hepatitis C infection. Subjects were excluded if they had a history of CNS opportunistic infections or non-HIV-related developmental, neurologic, psychiatric, or metabolic conditions that might affect CNS functioning. The methods for neuropsychological evaluation consisted of a battery of tests, including learning, memory, attention, speed of information processing, abstraction, and verbal and motor skills, as described previously. 12 For this study, the neurocognitive status of cases was termed neurocognitively normal, mild to moderate neurocognitive impairment (included cases of subsyndromal/asymptomatic and minor cognitive motor disorder), and severe neurocognitive disorder (equivalent to HIV dementia).
Standard protocol approvals, registration, and patient consents. We obtained postmortem brain tissue already banked at HNRC under the California NeuroAIDS Tissue Network study. Approval for the parent study was received from the local institutional review board. Written consent for research was obtained from all the patients participating in the study and donating tissue.
Analysis of HIV DNA, RNA, and p24 and category classification. DNA and RNA were extracted from frozen human frontal cortex samples with DNeasy mini kit and RNeasy Lipid tissue mini kit (Qiagen, Hilden, Germany). Quantification of HIV-1 DNA was performed at the HIV Neurobehavioral Research Program, Neurovirology Core (UCSD), under standard protocols on 50 ng of DNA. HIV RNA in the brain was quantified by qPCR using HIV-1 pol standard (provided by the HIV Neurobehavioral Research Program, Neurovirology Core) and GAPDH standard (Invitrogen, Carlsbad, CA). Copy number of HIV-1 was normalized to 1310 6 copies of GAPDH standard. Total protein homogenates were prepared from flash-frozen postmortem frontal cortex samples as described. 13 HIV-1 p24 was quantified by ELISA (PerkinElmer, Waltham, MA) on homogenate aliquots containing 20 mg of total protein. Immunocytochemical analysis. Vibratome sections from midfrontal cortex (40 mm thick) from control and HIV cases were processed as described 15 using antibodies against MAP2 (dendritic marker, 1:200, Millipore) and synaptophysin (presynaptic marker, 1:500, Millipore). 15, 16 Immunolabeled blind-coded sections were serially imaged with LSCM (MRC1024, Bio-Rad) and analyzed with Image 1.43 program (NIH), as described. 17 Among the 32 cases, antemortem neurocognitive diagnosis was available for 23 subjects, representing 75% of HIV1 controls (9 of 12), 80% of HIV1 latent cases (8 of 10), and 60% of HIVE cases (6 of 10) (table 1). Severe neurocognitive impairment was only reported for cases with HIVE. Mild to moderate neurocognitive impairment occurred in 6/8 (75%) of the latent cases as compared to 5/9 (56%) of the control cases. The relatively high rate of mild impairment in the control cases may reflect brain injury that occurred before HAART became available to these subjects, who were typically infected for a decade or more.
To understand the anatomical correlates to latent HIV infection, we analyzed neurodegeneration by confocal microscopy ( and Iba1 (figure 1, G and K) accompanied by the presence of p24 immunostained microglial cells (no p24 immunoreactivity was detected in HIV controls or in latent HIV cases, not shown).
Silencing of HIV-1 transcription in microglial cell cultures is mediated by the transcriptional regulator BCL11B, which recruits a multienzymatic chromatinmodifier complex to repress gene expression. 11 We therefore analyzed the levels of BCL11B and other components of the chromatin-remodeling complex in human brain samples. BCL11B protein was significantly higher in the latent group than in control and HIVE cases ( figure 2, A and B) . Consistently, BCL11B immunoreactivity was elevated in neuronal (figure 2, C and D) and glial cells (figure 2, C and E) in frontal cortex and white matter from latent HIV cases. Double labeling analysis confirmed that high levels of BCL11B were detected in microglial (figure 2, F and G) and astroglial cells (figure 2, H and I) only in the latent HIV cases, where p24 was not detectable, supporting the role of BCL11B in silencing HIV-1. On the contrary, in HIVE cases, p24-positive glial cells were negative for BCL11B (figure 2, G and I). No apparent changes in BCL11B mRNA levels were detected in the studied groups (figure e-1 on the Neurology ® Web site at www.neurology.org), suggesting that increased BCL11B associated with latency might be regulated at the level of protein translation or stability. To evaluate whether alterations of BCL11B in the brain might translate into peripheral fluids, similar analyses were performed in CSF samples. CSF from latent HIV cases showed increased BCL11B in comparison to the HIVE group (figure 2, J and K). We next investigated the levels of other components of the HIV-silencing complex ( figure 3) . HP1a, MeCP2, and HDAC1 were significantly increased in latent cases in comparison to HIVE samples ( figure 3, A, B , D, and F), while similar levels of HDAC2, SP1, and SUV39H1 were observed among all groups (figure 3, A, C, E, and G). As reported for BCL11B, upregulation of chromatin modifiers seems to operate at the protein level, without significant changes in gene expression (figure e-1).
BCL11B is an important transcriptional regulator in the brain. 14, 18 Since transcription of several genes, including those involved in apoptosis and cell death, is altered in HIV-1 infected brains, 19 we investigated whether this functional group of genes might represent a cluster of BCL11B targets by in silico analysis of the presence of BCL11B consensus sites. 20 Interestingly, 18 out of 25 candidate genes contained at least one canonical binding site for BCL11B in their proximal promoter region (table e-1). Among them, CEBP, CD74, CXCR4, SOX9, CFLAR, and PDCD6 have the highest representation of sites, and therefore are the most likely targets for BCL11B-mediated regulation. Analysis of their relative abundance in frontal cortex samples by qPCR revealed that CEBP was reduced (figure 4A) and CD74 and CXCR4 were elevated in the HIV1 latent group ( figure 4, B and C). Since these genes are involved in proinflammatory responses, we extended our analysis to include prominent inflammatory markers. We detected a decrease in IL-1 transcription ( figure 4D) , while significant upregulation of IL-6 was observed in latent HIV cases ( figure 4E ). Furthermore, CD74 and CXCR4 proteins were increased in the HIV latent group and, to a lesser extent, in HIVE cases when compared to HIV controls (figure 4, G-I). Similarly, CD74 and CXCR4 immunoreactivity were elevated in neurons and microglial cells from latent HIV and HIVE cases, in comparison to control samples (figure 4, J, L, and M). IL-6 immunoreactivity was also elevated in the astroglial cells in the latent group (figure 4, J and K). DISCUSSION We investigated the neuropathologic and molecular alterations associated with CNS latent HIV-1 infections, defined as cases displaying proviral DNA in the brain with no productive infection. Our results suggest that patients with latent HIV display cognitive deficits, neurodegenerative alterations, and neuroinflammatory changes, supporting the notion that viral latency is not innocuous for the brain and might represent a distinct condition with particular pathologic features. Although HIV1 latent and HIVE cases displayed similar clinical and neurodegenerative traits, the extent of the cognitive and pathologic alterations was greater in the HIVE group. At the molecular level, latent cases showed increased BCL11B protein levels, a transcriptional regulator that mediates silencing of the integrated provirus, while this epigenetic modulator of HIV infection was reduced in HIVE cases. Previous studies suggest that CNS is an important reservoir for HIV where proviral DNA and productive infections can be detected. 8, 21 Although HAART greatly benefited infected patients, it is unable to cure the infection due to the persistence of long-lived transcriptionally silent proviruses that can integrate into the host genome in subpopulations of susceptible cells, generating viral reservoirs in peripheral blood and organs. The brain, in particular, represents a sanctuary for HIV-1 latency, where the provirus can persist due to the variable and poor penetration of antiretroviral drugs. 22, 23 While viral replication was considered necessary for inflammation and neurodegeneration, recent studies showed a high prevalence of HAND even in long-standing aviremic patients. 24 We provide here a novel explanation for brain damage in the absence of viral replication, mediated by deregulation of BCLL1B that contributes to sustain HIV-1 latency and might also alter the expression of inflammationrelated genes.
Neuroinflammatory responses play important roles in neurodegeneration in HIV1 latent and HIVE groups, but based on BCL11B analysis, the pathways leading to inflammation might differ among groups. In HIVE, it has been proposed that HIV-infected monocytes cross the blood-brain barrier early on during infection and subsequently initiate a cascade of inflammatory mechanisms through the release of progeny virus/viral protein and cytokines/chemokines. 25, 26 Migrating infected monocytes express IL-1, IL-6, tumor necrosis factor (TNF)-a, tumor growth factor-b, GM-CSF, and prostaglandin E 2 , 27 which bind glia receptors and activate additional inflammatory genes through a positive feedback mechanism. In addition to neuroinflammation mediated by physiologic cellular molecules, monocyte-expressed HIV proteins, vpr, tat, nef, and gp120 activate interferon, apoptosis, and MAPK pathways in microglia and astrocytes contributing to chronic inflammation and neurotoxicty. [28] [29] [30] [31] In contrast, we propose that in patients with latent HIV infections, increased levels of BCL11B might directly trigger neuroinflammatory cascades by transcriptional deregulation of CD74, IL-6, and TNF-a. Although we cannot exclude that the cases we classified here as HIV1 latent could have previously been HIVE manifestations in which effective HAART suppressed viral replication, this possibility seems unlikely, since 50% of the subjects of the latent group never received HAART and the remaining only followed the treatment intermittently, favoring the idea that absence of viral RNA resulted from bona fide silencing mechanisms.
HIV-1 latency requires a successful integration event, where the host chromatin environment plays a key role. 8 In microglial cells, BCL11B assembles a multienzymatic complex by recruiting SP1, HP1a, HDAC1, HDAC2, and SUV39H to the viral LTR region, and establishing a heterochromatic environment at the viral insertion site silencing HIV-1 transcription. 11 In the present work, we investigated for the first time the status of BCL11B and associated epigenetic factors in the human brain in the context of HIV-1 infection. We report increased BCL11B, HP1a, MECP2, and HDAC1 in latent HIV infection, most probably due to posttranscriptional mechanisms, including protein translation or turnover. BCL11B is a common regulator of gene transcription in the brain 14 implicated in the negative regulation of BDNF signaling, which is altered in several neurodegenerative disorders. 18 Our results suggest that recruitment of BCL11B to the viral insertion sites during latency might alter the transcription of its target proinflammatory genes, triggering chronic inflammatory responses. We suggest that the presence of silent provirus in the brain might trigger chronic pathology and might be associated with neurocognitive impairment in latently infected patients.
Diagnosis of HIV-1 infection in the CNS can be achieved by detection of HIV in the CSF; still, the presence of latent viral forms can only be corroborated postmortem, hindering efforts to detect resident virus earlier to determine possible therapeutic interventions. An important outcome of the present work is the observation of abnormal BCL11B levels in the CSF of latently infected patients, in correlation with alterations in the brain. Further investigation will determine the potential use of BCL11B as biomarker of silent HIV-1 infections in the CNS.
The recent discovery of involvement of histone methylases and deacetylases in HIV latency fueled research aimed to reactivate latent reservoirs and to facilitate eradication by targeting actively replicating virus. 32 Valproic acid and trichostatin A were unable to reactivate HIV in latently infected primary CD4 T cells, 33 raising concerns about their potential use in neuroAIDS. Modulation of BCL11B could represent an alternative therapeutic strategy for eradication of reservoirs.
Taken together, our results suggest that latent HIV-1 infection in the CNS might be associated with increased levels of chromatin modifiers, including BCL11B. Alteration of these epigenetic factors might activate proinflammatory cascades associated with neurodegeneration and neurocognitive impairment. BCL11B and other silencing factors might represent novel targets to ameliorate the effects of HIV-1 infections in the CNS.
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